Athira Pharma Inc.

1.78+0.0250+1.42%Vol 359.75K1Y Perf -40.51%
Dec 6th, 2023 16:00 DELAYED
BID1.61 ASK1.89
Open1.75 Previous Close1.76
Pre-Market- After-Market1.77
 - -  -0.01 -0.56%
Target Price
16.75 
Analyst Rating
Moderate Buy 2.00
Potential %
841.01 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
14.61 
Earnings Rating
Market Cap67.74M 
Earnings Date
9th Nov 2023
Alpha-0.06 Standard Deviation0.23
Beta2.58 

Today's Price Range

1.671.84

52W Range

1.334.41

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
24.91%
1 Month
13.23%
3 Months
-20.95%
6 Months
-44.98%
1 Year
-40.51%
3 Years
-93.08%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ATHA1.780.02501.42
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
21.70
22.30
0.01
0.01
-20 459.80
Leverage Ratio 1.00
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.87-0.870.00
Q02 2023-0.81-0.783.70
Q01 2023-0.66-0.73-10.61
Q04 2022-0.70-0.79-12.86
Q03 2022-0.67-0.5320.90
Q02 2022-0.66-0.651.52
Q01 2022-0.63-0.5611.11
Q04 2021-0.61-0.3739.34
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.87
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume359.75K
Shares Outstanding38.05K
Shares Float26.79M
Trades Count1.36K
Dollar Volume635.59K
Avg. Volume245.57K
Avg. Weekly Volume295.61K
Avg. Monthly Volume268.66K
Avg. Quarterly Volume172.43K

Athira Pharma Inc. (NASDAQ: ATHA) stock closed at 1.755 per share at the end of the most recent trading day (a 4.46% change compared to the prior day closing price) with a volume of 324.32K shares and market capitalization of 67.74M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. Athira Pharma Inc. CEO is Leen Kawas.

The one-year performance of Athira Pharma Inc. stock is -40.51%, while year-to-date (YTD) performance is -44.64%. ATHA stock has a five-year performance of %. Its 52-week range is between 1.33 and 4.41, which gives ATHA stock a 52-week price range ratio of 14.61%

Athira Pharma Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 0.50, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -27.00%, a ROC of -28.44% and a ROE of -28.04%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Athira Pharma Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.87 for the next earnings report. Athira Pharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Athira Pharma Inc. is Moderate Buy (2), with a target price of $16.75, which is +841.01% compared to the current price. The earnings rating for Athira Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Athira Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Athira Pharma Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.14, ATR14 : 0.13, CCI20 : 190.13, Chaikin Money Flow : 0.26, MACD : -0.02, Money Flow Index : 85.27, ROC : 11.08, RSI : 59.63, STOCH (14,3) : 95.95, STOCH RSI : 1.00, UO : 56.07, Williams %R : -4.05), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Athira Pharma Inc. in the last 12-months were: James A. Johnson (Buy at a value of $12 000), Kevin Church (Option Excercise at a value of $17 307), Moebius Hans (Option Excercise at a value of $10 641)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (50.00 %)
2 (50.00 %)
2 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (50.00 %)
2 (50.00 %)
2 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

Athira Pharma Inc.

Athira Pharma Inc is a bio-technology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.

CEO: Leen Kawas

Telephone: +1 206 221-8112

Address: 4000 Mason Road, Seattle 98195, WA, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

48%52%

Bearish Bullish

58%42%

Bearish Bullish

53%47%

 

News

Stocktwits